BNP Paribas upgraded Genmab (GMAB) to Outperform from Neutral with a DKK 2,400 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab upgraded to Buy from Neutral at Goldman Sachs
- Genmab: Late‑Stage Pipeline De‑Risking and 2026 Catalysts Create Compelling 25% Upside Despite Darzalex LOE Overhang
- Genmab Updates Articles of Association to Expand Capital-Raising and Incentive Flexibility
- Genmab Registers AGM-Approved Share Capital Reduction After Cancelling 1.9 Million Treasury Shares
- Genmab Discloses Orbis as New 4.85% Major Shareholder